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1. Introduction 
Cystic Fibrosis (CF) is a disease with an evolving definition. Through earlier diagnosis and 
newborn screening programs, as well as a robust world-wide research program, we are able 
to treat individuals afflicted with this life-threatening malady more aggressively and with 
earlier interventions. Despite our progress in extending the life expectancy of the typical CF 
patient, the disease is still viewed by the general medical community as one of childhood.  
 
 
 
 
Source: Cystic Fibrosis Foundation Patient Registry Annual Data Reports, 1986-2009 
Fig. 1. Prevalence of Cystic Fibrosis in North American Adults 
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This former “age constraint” on the natural history of CF is paralleled by other major 
developments, such as an expansion of the number of organ systems, which we now know 
are involved in this disease. We now know that this disease affects more than the 
pulmonary and gastrointestinal systems.  
With the aging of the CF population (Figure 1), it has come to light that CF patients suffer 
from an increased risk of Diabetes Mellitus (Fischman & Nookala, 2008; Stecenko & Moran, 
2010), Osteoporosis (Haworth, 2010), and malignancies (Hernandez-Jimenez et al., 2008). 
There is also a growing body of literature suggesting that as a result of treating other 
conditions associated with CF and as a result of the inflammatory and immunologic milieu 
associated with Cystic Fibrosis, these patients also suffer from renal disease (Stephens & 
Ridden, 2002; Katz et al., 1988) (Figure 2). In this chapter, we will discuss our current 
understanding of Cystic Fibrosis and review potential associations to renal disease with 
special attention to glomerulonephritis (GN).  
 
 
 
 
 
Source: Cystic Fibrosis Foundation Patient Registry Annual Data Reports, 1996-2006 
Fig. 2. Prevalence of Cystic Fibrosis Patients Requiring Dialysis for Renal Failure 
2. Background - Cystic Fibrosis 
2.1 Genetics 
Cystic Fibrosis is the most common, lethal, autosomal recessive disorder seen among the 
Caucasian population. For this reason, its disease prevalence throughout much of the world 
is 1 in 2,000 to 1 in 3200 individuals. Among non-Caucasian populations, and those not 
living in North America or Western Europe, the prevalence is approximately 1 in 4,000 to  
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Legend: ABPA = Allergic Bronchopulmonary Aspergillosis,  
CFRD = Cystic Fibrosis-Related Diabetes Mellitus 
Fig. 3. Common Signs and Symptoms of Cystic Fibrosis, by Stage of Life 
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1 in 20,000 (Figure 4) (Sullivan & Freedman, 2009). Although we have known for decades of 
the association between salty sweat, obstructive lung disease, and pancreatic insufficiency, 
which comprise the hallmark symptoms of CF, and it was postulated as early as 1949 that a 
gene defect was the cause of CF, it was not until 1989 that the gene defect was localized to 
chromosome 7 (Rowe et. al., 2005). Since that time, more than fifteen hundred mutations 
have been identified that can lead to the cystic fibrosis phenotype (Boyle, 2007).  
 
 
 
 
Source: Cystic Fibrosis Foundation Patient Registry Annual Data Report 2009 
Fig. 4. Racial Demographics of Cystic Fibrosis Patients in North America 
This specific gene encodes a protein called the Cystic Fibrosis Transmembrane 
Conductance Regulator (CFTR), which is found on many different types of cells. CFTR 
plays numerous regulatory roles throughout the body. The role most commonly 
associated with CFTR is that of chloride channel. However, the CFTR protein also plays a 
role in the inhibition of sodium transport, the regulation of ATP channels, and the 
inhibition of calcium-activated chloride channels. We now know that there are multiple 
types of CFTR gene mutations. They range in effect from complete lack of protein 
production (Class I Mutation), and defective protein processing and trafficking to the cell 
surface (Class II), to reduced production of normal-functioning CFTR protein (Class V) 
(Sullivan & Freedman, 2009) (Table 1). The F508del mutation, which accounts for two-
thirds of Cystic Fibrosis in Northern Europe and North America, is a class II mutation, 
resulting in production of a defective CFTR protein. 
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Mutation 
Class 
Effect on CFTR Protein 
CFTR Ability 
to Function 
Pancreatic Exocrine 
Dysfunction 
I Protein not produced No Severe 
II 
Protein trafficking defect with CFTR 
degraded in ER/GolB; 
 
CFTR does not reach cell membrane
No Severe 
III 
Defective protein regulation; 
 
CFTR reaches cell membrane but not 
activated by ATP or cyclic AMP
No Severe 
IV 
Reduced Cl transport through apical 
membrane CFTR
Yes Mild 
V 
Splicing defect with reduced production 
of functioning CFTR
Yes Mild 
VI 
CFTR reaches cell membrane, but more 
rapid CFTR turnover
Yes Presumably Mild 
Legend: CFTR = Cystic Fibrosis Transmembrane Regulator Protein, ER = Endoplasmic Reticulum,  
GolB = Golgi Body, ATP = Adenosine Triphosphate, AMP = Adenosine Monophosphate, Cl = Chloride ion 
Table 1. CFTR Mutation Classes 
Since Cystic Fibrosis is an autosomal recessive genetic trait, full expression of this disease 
requires that a defective gene be present on each chromosome. However, having one 
abnormal gene typically conveys a milder level of morbidity. As the level of CFTR metabolic 
regulatory function decreases below fifty percent, the chance of the individual developing 
sino-pulmonary conditions such as sinusitis, nasal polyps, or asthma increases. Men with the 
cystic fibrosis trait may experience infertility due to Congenital Bilateral Absence of the Vas 
Deferens (CBAVD). Despite the fact that it takes the presence of only one abnormal CFTR gene 
and fifty percent CFTR function for sino-pulmonary and genitourinary symptoms to occur; it 
typically takes CFTR function at levels less than five-percent of normal, usually seen with two 
mutations, before a patient’s sweat chloride excretion rises to levels diagnostic of CF. 
Furthermore, it takes CFTR protein function to be decreased by ninety-nine percent for 
pancreatic insufficiency to occur (Strasbaugh & Davis, 2007). Moreover, despite our efforts to 
characterize the association between genetic defect and phenotypic disease, neither sweat 
chloride level nor pulmonary function test values correlate with number or type of CFTR 
mutation. In two studies looking at this association, the mutation known to lead to Cystic 
Fibrosis could be found in only three out of five patients (Groman et. al., 2005; Groman et al., 
2002). However, it is interesting that a 2009 study of urinary protein excretion with regard to 
Cystic Fibrosis did find an apparent association between level of renal protein excretion and 
genotype, suggesting that although we cannot directly correlate gastrointestinal or pulmonary 
phenotype with a patient’s genotype, we may be able to correlate renal phenotype with CF 
genotype (Cemlyn-Jones & Gamboa, 2009). 
2.2 Pathophysiology 
The pathophysiology of Cystic Fibrosis results from abnormalities localized to the CFTR 
gene site resulting in an abnormality in CFTR protein production or processing. Either 
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through this absence of CFTR protein, or through the production of abnormally functioning 
protein, an electrolyte imbalance occurs on luminal surfaces in multiple organ systems. The 
common result is the production of thick, tenacious secretions, which have impaired 
immunologic function and result in dysregulation of the patient’s inflammatory response, 
leading to an imbalance between pro-inflammatory and anti-inflammatory chemokines. In 
addition, there has been some evidence to suggest that the abnormal CFTR protein may 
facilitate protein binding of bacteria, leading to CF-related lung disease involving such 
bacterial pathogens as Pseudomonas aeruginosa and Staphylococcus aureus (Sullivan & 
Freedman, 2009; Rowe, 2005).  
2.3 Diagnosis 
The diagnosis of Cystic Fibrosis is typically made based on a combination of clinical 
symptoms consistent with the disease along with confirmatory testing. Since 1959, the 
diagnostic standard for Cystic Fibrosis has been the measurement of sweat chloride levels, 
as stimulated through a process using Pilocarpine Iontophoresis. In children younger than 
six months of age, a normal concentration of sweat chloride is considered to be less than 30 
mmol/liter. In patients older than six months, the normal range would be less than 41 
mmol/liter. Regardless of age, any repeatable sweat chloride level greater than 59 
mmol/liter is consistent with the diagnosis of Cystic Fibrosis, particularly if accompanied by 
symptoms of sino-pulmonary disease, a gastrointestinal malady such as fat-soluble vitamin 
deficiency, malnutrition, or intestinal obstruction, metabolic alkalosis, dehydration, or acute 
salt depletion (Figure 2) (Farrell et al., 2008).  
Consistent with the phenotypic pancreatic insufficiency seen in 90-95% of Cystic Fibrosis 
patients, pancreatic enzyme levels may be measured to help confirm the diagnosis. As of 
2010, fourteen European countries and all states in the United States have a process in place 
for screening newborns for this disease. Most of these testing programs, at least to some 
degree, rely on measuring levels of Immunoreactive Trypsinogen, a pancreatic enzyme 
found to be elevated in the first six weeks of life in infants with CF (Barto & Flume, 2010). 
In the situation where the sweat chloride analysis is indeterminate or the symptomatic 
phenotype is subtle, genetic testing is often employed. If the patient is found to have two 
mutations known to be consistent with the cystic fibrosis phenotype, then the diagnosis can 
be made. If one mutation is found, and it is unclear if the patient has a second, less well-
characterized mutation, then the patient is considered to have a possible diagnosis of Cystic 
Fibrosis. As noted previously, genetic testing may still be performed in the circumstance of 
confirmed disease, since the patient’s specific mutations may have prognostic significance. 
Furthermore, as we attain a greater understanding of the myriad of ways that defective 
CFTR genes may lead to inadequate or defective protein production and function, we will 
be able to tailor our therapeutic regimens more effectively to the patient’s genetic 
circumstance, in order to modulate or restore CFTR function (Ashlock et al., 2009). 
2.4 Clinical manifestations 
To date, it has been impossible to draw a direct link between the degree of genotypic 
abnormality and a particular patient’s morbidity. However, there are some common clinical 
patterns and associations seen in cystic fibrosis patients. Based on these clinical findings, an 
all-encompassing definition of Cystic Fibrosis would be “a chronic and progressive, multi-
system disease leading to sino-pulmonary disease, with probable exocrine pancreatic 
insufficiency, malnutrition, and gastrointestinal obstructive symptoms”. Patients with 
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Cystic Fibrosis typically have some degree of obstructive lung disease and present with a 
distinguishing factor of early colonization and subsequent infection from organisms not 
typically seen except in immunosuppressed or severely bronchiectatic individuals, such as 
Pseudomonas aeruginosa, Burkholderia cepacia, or Stenotrophomonas maltophilia. 
As a consequence of pancreatic insufficiency and associated malnutrition, many Cystic 
Fibrosis patients are deficient in fat soluble vitamins and suffer from a chronic, negative 
protein balance. Mouse studies have shown that the presence of CFTR gene defects leads to 
a heightened risk of Osteoporosis and subsequent bone fracture (Haworth, 2010). Along 
with this fracture risk, CF patients have an increased risk of kidney stones. One autopsy 
study of thirty-eight CF patients found that thirty-five had evidence of nephrocalcinosis, 
including one still-born and two neonatal infants (Katz et al., 1988). This predilection seems 
to be multifactorial and results from the interplay of 1) impaired vitamin D absorption 
leading to impaired calcium absorption, 2) chronic disease characterized by increased 
metabolic tempo, 3) immobility, 4) increased osteoclast activity, 5) inadequate caloric intake 
due to increase work-of-breathing, 6) an imbalance between protein anabolism and 
catabolism, and 7) loss of oxalate-degrading bacteria due to frequent, and often chronic 
antibiotic use (Stephens & Rigden, 2002). Furthermore, Andrieux et al., in their 2010 study, 
found that 75% of children in their study population had hypocitraturia and 70% had 
hyperoxaluria, both of which are risk factors for nephrolithiasis (Andrieux et al., 2010). 
One interesting aspect of the renal expression of CFTR is that cystic fibrosis patients often 
have greater antibiotic excretion than their non-CF counterparts. This necessitates the use of 
higher-than-typical antibiotic doses. The classic example of this occurs with the use of 
aminoglycoside antibiotics for treatment of pseudomonal infections, where Tobramycin is 
dosed at 10 mg/kg, sometimes in conjunction with inhaled Tobramycin, instead of the usual 
5-7 mg/kg (Barto & Flume, 2010, Bergman et al., 2007). Indeed, in one study of renal failure 
in children with Cystic Fibrosis, twenty of twenty-four cases of acute renal failure were 
associated with recent or concomitant aminoglycoside administration (Bertenshaw et al., 
2007). As a result of this uncertain pharmacokinetic and pharmacodynamic profile 
encountered with cystic fibrosis patients, monitoring drug levels is critical to insure that 
therapeutic doses are being achieved for efficacy.  
3. Renal disease and the CF patient 
3.1 A broad picture of renal disease in Cystic Fibrosis 
Since Dorothy Anderson first generated the term, “Cystic Fibrosis,” in 1938, we have 
known that kidney disease may be part of this malady (Abramowsky & Swinehart, 1982). 
However, the natural history of CF-related renal disease has been elucidated in few 
studies. In Abromowksy and Swinehart’s 1982 study, they found that all thirty-four of the 
patients studied had some form of glomerulopathy, with nineteen having 
glomerulosclerosis. Twenty-five had what was described as a “Mesangiopathy,”and 
twenty-six had tubulointerstitial disease. In this study, the authors concluded that a 
number of factors had led to the myriad of renal lesions observed: 1) lung disease with 
resultant cyanosis, 2) liver disease, 3) Cystic Fibrosis-Related Diabetes Mellitus, 4) the 
effects of nephrotoxic medications, and 5) an altered immune response. Of note, the 
authors report that sixteen of thirty-four patients studied had complement-3 (C3) deposits 
in their kidneys while thirteen had evidence of immunoglobulin–M deposits (IgM) 
(Abramowsky & Swinehart, 1982). 
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A more contemporary, 2010 study investigating renal disease in Cystic Fibrosis followed 112 
children, starting in the first year of life. This study revealed the presence of 
microalbuminuria in fifty-eight percent of patients. This finding was attributed to the 
presence of chronic inflammation as a result of the malfunctioning or absent CFTR protein, 
repeated infections, and the nephrotoxicity of many medications commonly used in the 
treatment of CF (Andrieux et al., 2010). Furthermore, a 2009 study following five hundred 
ten adults with CF, median age of thirty-one years, found that 13 developed renal disease 
severe enough to warrant renal biopsy, with eight different types of nephropathies found on 
histologic analysis. Twelve of these thirteen patients were found to have glomerular lesions. 
In this study, the main types of renal disease found were AA amyloidosis and diabetic 
nephropathy (Yahiaoui et al., 2009).  
In literature reviewed for their 2002 article on renal disease in Cystic Fibrosis, Stephens and 
Rigden report that IgA Nephropathy appeared to be the most common form of 
glomerulonephritis described in CF patients, though the occurrence of this condition appeared 
rare (Stephens & Rigden, 2002). With respect to all renal disease in CF patients, the most 
common renal pathology found has been nephrocalcinosis. Drug-related nephrotoxicity also 
continues to be a common cause of renal morbidity among CF patients. Among the various 
agents responsible medication-induced renal disease, aminoglycosides continue to play a 
prominent role. As a result of the pharmacodynamic and pharmacokinetic eccentricities of the 
cystic fibrosis patient, Acute Tubular Necrosis (ATN) remains a constant concern when 
treating pulmonary exacerbations in this patient population. This risk of ATN is amplified by 
pulmonary biofilm formation and the need to use a combination of intravenous, oral, and 
inhaled antibiotics to effect a decrease in pathogen levels, and potentially facilitate bacterial 
eradication. It is for this reason that current Cystic Fibrosis Foundation guidelines recommend 
once-daily dosing of aminoglycosides to optimize treatment benefit, yet minimize risk of renal 
injury (Flume et al., 2009). Furthermore, a 2010 review of aminoglycoside toxicity in cystic 
fibrosis patients suggested that use of once-daily Tobramycin, particularly when dosed in the 
morning, may be superior to use of gentamicin in preventing aminoglycoside-induced renal 
injury (Prayle & Smyth, 2010) (Figure 4). 
3.2 Measurement of renal function in CF patients 
Discussion of renal disease in CF patients is complicated by the fact that conventional 
methods of measuring renal function may not be accurate in this population (Prayle & 
Smyth, 2010). In Andrieux’s 2008 study of renal disease in children with CF, his team 
observed that there was no correlation between a calculated Glomerular Filtration Rate 
(GFR), using the Schwartz Formula’s manipulation of serum creatinine (SCr) values, and a 
urine creatinine-based (UCr) standard.  
Schwartz Formula:  
GFR(mL/min/1.73 m2) = ((k)(Height in cm)/(SCr in mg/dL)) where  
K = Constant as follows: 
 0.33 in premature infant 
 0.45 in term infants to 1 year-old 
 0.55 in children older than one, up to 13 years old 
 0.55 in adolescent females 
 0.65 in adolescent males  
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In one-third of children studied, the Schwartz Formula’s serum-creatinine derived approach 
overestimated renal function (Andrieux et al., 2010). Furthermore, Yahiaoui’s 2009 study 
investigating renal disease in thirteen adults with Cystic Fibrosis concluded that one of the 
reasons that renal disease is considered uncommon in CF patients is that measurements of SCr 
and calculations of GFR, using either the Cockcroft-Gault or MDRD equations, fail to 
adequately and reliably reflect a CF patient’s true level of kidney function (Yahiaoui et al., 2009).  
To explain this apparent inadequacy in SCr-based evaluation of renal function observed in 
the CF population, it has been suggested that decreases in muscle mass seen among CF 
patients, and typically related to their underlying disease states, leads to decreased 
production of SCr. This would hinder the proportional rise in SCr levels in response to renal 
insufficiency, which has been observed in other studied populations. Recognizing this 
challenge of accurately measuring renal function in CF patients, methods that more directly 
measure kidney function have been proposed including methods using UCr collection, 
typically over twenty-four hours or using plasma levels of an inert tracer which is only 
excreted via the kidneys (Prayle & Smyth, 2010). 
In recognizing the fallacies of SCr-based formulae, the difficulties of collecting urine 
accurately over an extended period of time, and the invasiveness of nuclear tracer-based 
measurements of renal function, Beringer and colleagues studied levels of the biomarker 
Cystatin C (Cys C) as a potential method of estimating GFR. Their study showed that 
measurement of Cystatin C clearance was a suitable alternative to measurement of SCr or 
calculated GFR in following a CF patient’s renal function. Furthermore, Cys C levels were 
not affected by age, gender, muscle mass, diet, or level of physical activity. Moreover, the 
authors make specific mention of using this method to follow CFRD patients for evidence of 
renal disease (Beringer et al., 2009). Unfortunately, at this time, Cys C levels have not 
become widely employed. 
3.3 Cystic Fibrosis-Related Diabetes Mellitus and Renal Disease 
Since Cystic Fibrosis-Related Diabetes Mellitus (CFRD) is becoming an increasingly common 
complication in the natural history of Cystic Fibrosis, and can lead to significant renal 
pathology, we discuss this type of renal disease as an independent section. By the time CF 
patients reach their thirtieth birthday, 45-50% will have developed CFRD, with an associated 
increase in morbidity and mortality. This complication of Cystic Fibrosis was formerly the 
most dreaded of sequelae, as it was associated with a six-fold increase in mortality, 
particularly among women (Fischman & Nookala, 2008). However, through aggressive efforts 
to increase screening for evidence of impaired glucose intolerance and overt diabetes, as well 
as through early use of oral diabetic medications and insulin, the mortality disparity associated 
with CFRD has all but disappeared (Stecenko & Moran, 2010) (Table 2).  
As with other forms of Diabetes Mellitus, CFRD may lead to microvascular changes in such 
structures as the Eyes, Kidneys, Stomach, and Nerves. A 2007 study of the microvascular 
complication of CFRD suggested that CFRD-related nephropathy occurred less commonly than 
renal complications seen in association with other forms of Diabetes Mellitus (Schwarzenberg et 
al., 2007). The results found in Schwarzenberg’s study appear to be consistent with our current 
understanding of CFRD, which suggests that the increased mortality risk that CFRD conveys is 
due to accelerated progression of the patient’s underlying lung disease, not due to vascular 
complications (Stecenko & Moran, 2010). Moreover, the microalbuminuria that we typically 
associate with microvascular damage to the kidney was only seen among CF patients who had 
fasting hyperglycemia (Schwarzenberg et al., 2007) (Table 3).  
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Characteristic CFRD DM I DM II 
Age at Onset 18-21 years < 20 years >40 years 
Prevalence 
22% of CFFR 
population (2% of 
children, 19% of 
adolescents, 45-50% 
over age 30a) 
7% of US population 
7% of US population (NB: 
> 15% of population > 50 
years) 
Body Habitus Thin Normal Overweight/Obese 
Insulin 
Secretion 
Decreased, Release 
delayed 
Absent Decreased relative to need 
Insulin 
Resistance 
Increased or 
Unchanged 
Increased Slightly Increased Dramatically 
Ketoacidosis No Yes No 
Microvascular 
Complications 
Yes Yes Yes 
Macrovascular 
Complications 
Extremely Rare Yes Yes 
Nutritional 
Support 
High calorie diet: (120-
150%) of RDA 
Fat: 40% of dietary 
intake (No restrictions 
on type) 
Protein: 10-20% of 
calories, not reduced for 
nephropathy 
Sodium: > 4 grams per 
day 
Vitamins: Routine 
supplementation 
Calories adjusted for 
goal: growth, weight 
maintenance, or loss 
Fat Restriction: <30% of 
total calories, <10% 
from saturated fats 
Protein: 10-20% of total 
calories; reduced for 
nephropathy 
Sodium: <2.4 grams per 
day 
Vitamin: 
Supplementation for 
diagnosed deficiencies 
Calorie restriction for 
weight loss 
Fat Restriction: <30% of 
total calories, <10% from 
saturated fats 
Protein: 10-20% of total 
calories; reduced for 
nephropathy 
Sodium: <2.4 grams per 
day 
Vitamin: 
Supplementation for 
diagnosed deficiencies 
Pharmacologic 
Therapy 
Insulin 
therapy(currently SOC); 
oral anti-diabetic 
agents(controversial) 
Insulin replacement; SC 
synthetic Amylin 
analogues 
Oral antidiabetic agents; 
Insulin therapy; SC 
Incretin Mimetic and 
synthetic Amylin 
analogues 
Legend: CFFR = North American Cystic Fibrosis Foundation Registry; DM I = Diabetes Mellitus Type I; 
DM II = Diabetes Mellitus Type II ; RDA = recommended daily allowance; SOC = standard of care;  
SC = subcutaneously administered. 
Table 2. A Comparison of Cystic Fibrosis-Related Diabetes Mellitus to Types 1 and 2 
Diabetes Mellitus 
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Glucose 
Tolerance 
Catergory 
Fasting Serum 
Glucose (mg/dl) 
Two-Hour Oral Glucose 
Challenge: One-Hour 
Value (mg/dl) 
Two-Hour Oral Glucose 
Challenge (mg/dl) 
Normal Glucose 
Tolerance 
<126  <140 
Indeterminate <126 >/= 200 <140 
Impaired Glucose 
Tolerance 
<126  140-199 
Impaired Fasting 
Glucose 
100-125   
CFRD without 
Fasting 
Hyperglcemia 
(CFRD FH-) 
<126  >/= 200 
CFRD with 
Fasting 
Hyperglycemia 
>/= 126  >/= 200 
Table 3. Cystic Fibrosis-Related Diabetes Mellitus Diagnostic Categories 
It is interesting that a subsequent 2008 study comparing microvascular changes found in CF 
patients to a matched cohort of patients with Type I Diabetes Mellitus (DM1) found that while 
retinopathy occurred more frequently in DM1, renal disease as measured through 
microalbuminuria occurred with greater frequency in patients with CFRD. The authors of this 
study explained this discrepancy in microvascular findings by speculating that other factors, 
such as deficient CFTR function, chronic inflammation, repeated exposure to nephrotoxic 
agents, or genetic predispositions may be the cause (van den Berg et al., 2008). While the 
results of these two studies may appear to be conflicting, a closer analysis reveals that van den 
Berg’s study methodology does not distinguish patients with fasting hyperglycemia from 
those without; thus, if van den Berg’s CFRD population had a preponderance of patients with 
fasting hyperglycemia, then the results of these two studies may be consistent. 
Within the last decade, case reports have emerged suggesting that Nodular 
Glomerulosclerosis (NGS) in cystic fibrosis patients may mimic the findings of Diabetic 
Nephropathy (DN) (Westall et al., 2004). Since the histopathology of these cases appears to 
be misleadingly reminiscent of that seen in Diabetic Nephropathy, we have chosen to 
discuss these cases in conjunction with our discussion of CFRD-related renal disease. In 
their case report, Westall’s team reports that all three patients had pathologic findings 
thought consistent with DN, including Kimmelstiel-Wilson Nodules, without any evidence 
of impaired glucose tolerance. The authors speculate that the Focal and Nodular 
Glomerulosclerosis observed (e.g. the Kimmelstiel-Wilson nodules) may be an idiopathic 
occurrence, may be the result of CFTR deficiency or abnormal function, or may be the result 
of accumulation of toxic molecules. The authors explain that these toxic molecules are 
generated as the byproduct of an inflammatory process or as a result of oxidative stress. 
Furthermore, they conjectured that these pathologic findings may be the consequence of 
undetected episodes of hyperglycemia, which would eventually become more persistent.  
In an accompanying editorial to Westall’s case series, Krous discusses the implications of 
Westall’s work. In his commentary, Krous does raise the question of whether we should be 
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routinely screening cystic fibrosis patients for proteinuria, since renal pathology similar to 
DN has been described, even without evidence of hyperglycemia. Krous also calls for 
further investigation of the specific pathologic process that leads to the NGS seen in both CF 
and Diabetes Mellitus. In the end, the only answer that Krous leaves us with is that it may 
be prudent to screen CF patients for proteinuria (Krous HF, 2004). 
3.4 Glomeulonephritis 
3.4.1 An introduction to glomerular disease in Cystic Fibrosis 
Despite the fact that renal pathology among Cystic Fibrosis patients was described from the 
time that CF’s constellation of symptoms was first delineated, there still remains relatively 
little written on renal involvement in CF. There are many explanations as to why this may 
be the case: lack of a clear CF renal disease phenotype, difficulty measuring renal 
impairment due to inadequacy of SCr-based renal function tests, and, possibly, reluctance of 
cystic fibrosis center care teams to pursue the presence of renal pathology with potentially 
intrusive, and possibly invasive testing (Yahiaoui et al., 2009). However, with the aging of 
this patient population, an increasing number of case reports have suggested that renal 
disease is part of the CF phenotype. In 1972, Openheimer described the presence of 
glomerular pathology in autopsied CF patients (Openheimer, 1972). Abramowsky’s 1982 
study showed that a majority of patients studied not only had evidence of glomerular 
involvement, but also immunoflourescence findings of immunoglobulin and complement 
deposition in glomeruli, with localization to the mesangial regions and capillary loops 
(Abramowsky & Swineheart, 1982). A more contemporary study of thirteen adults with CF 
and renal disease, who underwent a renal biopsy, revealed that twelve had glomerular 
lesions (Yahiaoui et al., 2009). Thus, it is clear that, beyond a CF patient’s very real risk of 
experiencing a renal injury as a result of a medication adverse drug reaction or toxicity, 
Cystic Fibrosis, itself, may be associated with renal pathology. In this section we will discuss 
the types of glomerular lesions that have been observed and current theories on the 
development of glomerular pathology in Cystic Fibrosis. 
3.4.2 IgA Nephropathy 
In Stephens and Rigden’s review of renal disease in Cystic Fibrosis, they report that among 
the glomerulonephritides, IgA Nephropathy is the most frequently reported (Stephens & 
Rigden, 2002). In a 1999 case series reported by Stirati and colleagues, four out of the five CF 
patients who underwent a renal biopsy for proteinuria had findings consistent with IgA 
Nephropathy. It should be noted that the authors do admit that since IgA Nephropathy is a 
common type of GN in young adults, and the patients in their study ranged in age from 
twenty-two to thirty years, their findings may be a chance occurrence.  
However, another plausible explanation for this association, put forth by the authors is that 
recurrent bacterial infections result in a robust immune response leading to increased levels 
of circulating immunoglobulins and immune complexes. These immune-mediating 
molecules may deposit in the kidney and lead to the histopathology and morbidity observed 
(Stirati et al., 1999). Interestingly, in Abromowsky and Swinehart’s 1982 study, the 
explanation of chronic bacterial infection leading to a high level of immune activity resulting 
in glomerular pathology was also raised. Abramowsky and Swinehart conjectured that the 
proximate cause was chronic pseudomonas aeruginosa infection. However, contemporary 
immunologic investigations using pseudomonas antiserum did not reveal any antigens in 
the studied glomeruli.  
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If chronic pseudomonal infection is not the nidus for this robust immune response, then 
what is? The answer may actually lie in staphylococcal infection. Staphylococcus 
epidermitis bacteremia and staphylococcus aureus-asssociated endocardititis have long 
been known to cause glomerulonephritis. Furthermore, histopathology of staphylococcal-
associated GN typically reveals glomerular immune complex deposits containing 
complement, particularly C3, and immunoglobulins, typically IgG and IgM. These 
findings are consistent with those described in CF-related Glomerulonephritis, and have 
even greater significance in light of the fact that staphylococcus remains a common 
colonizing pathogen (Figure 5), and a major cause of lung infection early in a CF patient’s 
life, typically causing pneumonia before pseudomonas aeruginosa infections become 
common. Moreover, idiopathic IgA Nephropathy is known to occur within a few days of 
the patient experiencing an upper respiratory infection. Thus, there appears to be a viable 
association between staphylococcal colonization and IgA Nephropathy in cystic fibrosis 
patients (Satoskar et al., 2006). 
 
 
Source: Cystic Fibrosis Foundation Patient Registry Annual Data Reports, 1986-2009 
Fig. 5. Prevalence of Staphylococcus Aureus Infection/Colonization Among Cystic Fibrosis 
Patients 
In a 2006 case series by Satoskar and colleagues, they report eight cases of staphylococcus 
infection-associated mesangial and/or intracapillary proliferative glomerulonephritis (GN) 
associated with IgA-laden immune complex deposition. In this study, seven of the eight 
patients described had infections other than endocarditis, and the eighth suffered from an 
epidural abscess which resulted in endocarditis (Satoskar et al., 2006). The reason why 
staphylococcal infections may lead to GN remains unclear. One theory proposed by 
Satoskar suggests that staphylococcus enterotoxins may behave as superantigens that bind 
Major Histocompatibility Complex Class II (MHC II) molecules on Antigen-Presenting Cells 
(APC). This complex of MHC II and enterotoxin then binds to T-cell receptors, resulting in 
widespread T-cell activation and a surge of cytokine release. These cytokines, in turn, 
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activate B-cells, which then produce IgA and IgG molecules. These immunoglobulins are 
then released, resulting in immune complex formation, and eventual deposition in the 
Kidney. Further elaborating on this mechanism of glomerular pathology, Koyoma’s group 
described a specific staphylococcus aureus envelope antigen as a proximate cause for 
superantigen formation (Koyoma et al., 2004). Thus, research studying the association 
between staphylococcal skin and wound infections, as well as idiopathic IgA Nephropathy, 
may shed some light on the pathologic association between IgA Nephropathy and Cystic 
Fibrosis. 
3.4.3 Membranoproliferative Glomerulonephritis 
The occurrence of Membranoproliferative Glomerulonephritis (MPGN) in cystic fibrosis 
patients is not a new finding. Ambrowsky and Swinehart’s 1982 autopsy study of thirty-
four Cystic Fibrosis patients showed eighteen patients who had evidence of immune 
complex deposition in the Kidney, and, of those, sixteen had evidence of mesangial 
proliferation with two also having evidence of membranoproliferative histopathology. 
Thus, this autopsy study would suggest that MPGN is a major cause of renal disease in 
the CF patient.  
However, more contemporary reviews of the subject do not find nor discuss MPGN in the 
CF patient (Stephens & Rigden, 2002; Yahiaoui et al., 2009). Indeed, the only recent report 
of this association was published by Soriano and colleagues in 2008 (Soriano et al., 2008). 
In this paper, the authors discuss multiple, plausible explanations for the natural history 
of renal disease in CF. One mechanism proposed, the Factor H Deficiency Model, is based 
on the observation that genetic knockout mice who are deficient in alternate complement 
pathway Factor H not only develop MPGN, but also experience higher mortality with 
pseudomonas aeruginosa infections than factor H sufficient mice. Furthermore, factor H 
deficiency has been found to lead to aberrant activation of Complement Factor C3 and 
higher serum levels of various chemokines and cytokines (Soriano et al., 2008). This 
pathologic explanation is supported by the work of Wisnieski’s group, who reported in 
1985 that mortality among their cohort of one hundred thirty-nine patients was highly 
associated with decreased alternate complement pathway function and the presence of 
circulating immune complexes (Wisnieski et al., 1985).  
Separate from the immunologic explanation proposed above, a plausible link between 
Cystic Fibrosis and Membranoproliferative Glomerulonephritis lies in the function of Toll-
like Receptors (TLR), which are part of the Innate Immune System. This family of receptor 
proteins is responsible for recognizing recurring structures on pathogens, including single-
stranded DNA, lipopolysaccharides, and RNA molecules. Upon recognition of a structure 
known to be associated with a pathogen, the TLR initiates inflammatory and immune 
responses whose end result is meant to be destruction of the pathogen. By modulating 
immune responses, including regulating helper T-cell immunologic responses, aberrant TLR 
function is conjectured to lead to kidney inflammation and glomerulonephritis (Smith & 
Alpers, 2005). A 2004 study by Muir and colleagues showed that TLR-2 expression was up-
regulated in the lungs of CF patients (Muir et al., 2004). Moreover, in 2006, Shuto and 
colleagues suggested that this TLR-2 up-regulation and prolonged activation was critical to 
the pathogenesis of CF lung disease (Shuto et al., 2006). Separate from the Factor H 
Deficiency or the TLR models for the development of glomerulonephritis in cystic fibrosis 
patients, the presence of staphylococcal superantigens has been conjectured to lead to 
MPGN in CF patients (Soriano et al., 2008). 
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3.4.4 Treatment 
To date, there has been very little written on the treatment of glomerulonephritis in CF 
patients. One available case series details the diagnosis and treatment of two adult patients. 
In this article, it is reported that one of the patients experienced an improvement in his renal 
disease to the point where he could safely forgo hemodialysis after undergoing a double-
lung transplant and starting his anti-rejection regimen (Soriano et al., 2008). This would 
suggest that the conventional immunosuppressant therapy typically employed in the 
treatment of glomerulonephritis would be appropriate in this population as well. However, 
given the known pharmacokinetic and pharmacodynamic intricacies of the CF patient, 
further study is warranted. 
4. Conclusion  
Cystic Fibrosis is a disease in evolution. Through wide-spread newborn screening programs, 
patients are diagnosed earlier. Through an aggressive, world-wide therapy development 
network, new and revolutionary treatments for the manifestations of Cystic Fibrosis are 
shepherded from the lab bench to the patient’s home. As we develop a better understanding 
of how genetic mutation translates into phenotypic dysfunction and symptoms, we will be 
able to regulate and modify protein function to ameliorate the symptoms of Cystic Fibrosis. 
However, with these revolutionary changes to how patients experience the morbidity of 
Cystic Fibrosis, and with the aging of the CF population, new manifestations of CF may 
emerge. Kidney disease, particularly glomerulonephritis, may be one of the more plausible 
morbidities to afflict CF patients with growing regularity in the future. Thus, we must stay 
ever vigilant, and not become complacent that we have a complete understanding of this 
disease process. Cystic Fibrosis is no longer a disease of children. We must, therefore, 
continue to broaden our understanding of what it means to be an adult with Cystic Fibrosis. 
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